encorafenib
Braftovi Approved to Treat BRAF-Mutated CRC in Combination With Erbitux
The FDA approved the use of encorafenib (Braftovi, Pfizer) in combination with cetuximab (Erbitux, ImClone) in ...
APRIL 21, 2020
FDA Approves Encorafenib and Binimetinib Combo for Melanoma With BRAF Mutations
The FDA approved the use of Braftovi and Mektovi in combination for patients with unresectable or metastatic ...
JUNE 29, 2018
Load more